Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Bessemer Group Inc.

Bessemer Group Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 23.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 121,072 shares of the biopharmaceutical company’s stock after purchasing an additional 23,213 shares during the quarter. Bessemer Group Inc.’s holdings in Gilead Sciences were worth $8,868,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Financial Counselors Inc. boosted its holdings in Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 128 shares during the last quarter. Steph & Co. boosted its holdings in Gilead Sciences by 1.9% in the 4th quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock valued at $611,000 after purchasing an additional 142 shares during the last quarter. First Affirmative Financial Network boosted its holdings in Gilead Sciences by 3.5% in the 1st quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 147 shares during the last quarter. Rathbones Group PLC boosted its holdings in Gilead Sciences by 3.7% in the 4th quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock valued at $339,000 after purchasing an additional 150 shares during the last quarter. Finally, MCF Advisors LLC raised its stake in shares of Gilead Sciences by 2.1% in the 1st quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock valued at $538,000 after acquiring an additional 152 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 3.3 %

Shares of Gilead Sciences stock traded up $2.33 during trading hours on Wednesday, hitting $73.50. The company had a trading volume of 6,596,089 shares, compared to its average volume of 7,435,855. The company’s 50-day moving average is $67.30 and its two-hundred day moving average is $71.17. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The company has a market cap of $91.57 billion, a P/E ratio of 197.69, a price-to-earnings-growth ratio of 3.10 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.37 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 3.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on GILD shares. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target on the stock in a research note on Monday, July 8th. Oppenheimer reissued an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. Finally, TD Cowen decreased their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Friday, April 26th. Twelve investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Gilead Sciences presently has an average rating of “Hold” and an average target price of $82.88.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.